Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tipiracil
Accession Number
DB09343
Type
Small Molecule
Groups
Approved, Investigational
Description

Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.2 TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF or anti-EGFR therapy.1

Structure
Thumb
Synonyms
  • 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione
  • 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1H-pyrimidine-2,4-dione
  • Tipiracil
  • Tipiracilo
Product Ingredients
IngredientUNIICASInChI Key
Tipiracil hydrochloride4H59KLQ0A4183204-72-0KGHYQYACJRXCAT-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
LonsurfTipiracil (8.19 mg) + Trifluridine (20 mg)TabletOralTaiho Pharma Canada, Inc.2018-03-22Not applicableCanada
LonsurfTipiracil (6.14 mg) + Trifluridine (15 mg)TabletOralTaiho Pharma Canada, Inc.2018-03-22Not applicableCanada
LonsurfTipiracil hydrochloride (8.19 mg/1) + Trifluridine (20 mg/1)Tablet, film coatedOralTaiho Pharmaceutical Co., Ltd.2015-09-22Not applicableUs
LonsurfTipiracil hydrochloride (6.14 mg/1) + Trifluridine (15 mg/1)Tablet, film coatedOralTaiho Pharmaceutical Co., Ltd.2015-09-22Not applicableUs
Categories
UNII
NGO10K751P
CAS number
183204-74-2
Weight
Average: 242.662
Monoisotopic: 242.057053323
Chemical Formula
C9H11ClN4O2
InChI Key
QQHMKNYGKVVGCZ-UHFFFAOYSA-N
InChI
InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)
IUPAC Name
5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
ClC1=C(CN2CCCC2=N)NC(=O)NC1=O

Pharmacology

Indication

Tipiracil, in combination with trifluridine, is indicated for the treatment of refractory mestastatic colorectal cancer patients who keep progressing despite of treatment with standard chemotherapy and biologics.3

Associated Conditions
Pharmacodynamics

Tipiracil prevents trifluridine conversion into 5-trifluoromethyl-2,4(1H,3H)-pyrimidinedione, which is an inactive major metabolite, by inhibiting the enzyme thymidine phosphorylase. Thus, tipiracil is able to increase trifluridine bioavailability. On the other hand, thymidine phsophorylase is a known platelet-derived endothelial cell growth factor and its inhibition generates an indirect antiangiogenic benefit.3

Mechanism of action

Tipiracil is a thymidine phosphorylase inhibitor. Its function prevents the breakdownof the active component of trifluridine, thus increasing the bioavailability of trifluridine and boosting its systemic presence.1 In addition, it is reported that thymidine phosphorylase is an angiogenic factor usually overexpressed in solid tumors.4 There is a direct association of thymidine phosphorylase with a poor prognosis; where the tumors with an elevated expression of this enzyme tend to present an increased angiogenesis and ergo, be more malignant. Therefore, it has been suggested that tipiracil presents an aditional function by downregulating tumoral angiogenesis.5

TargetActionsOrganism
AThymidine phosphorylase
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Absorption of tipiracil is suggested to be done by the gastrointestinal tract. 8 Administration of a single 35 mg/m2 dose of TAS-102 containing tipiracil and trifluridine, generates the absoprtion rates of tipiracil of AUC 301 ng h/ml, maximum observed plasma concentration (Cmax) 69 ng/ml and time for maximum observed plasma concentration (Tmax) 3 h. 6 The consumption of a high-fat and high-calorie meal can decrease Cmax and AUC by 40%.7

Volume of distribution

After a single TAS-102 dose if 35 mg/m2 in patients with advanced solid tumors, it was recorded a volume of distribution of tipiracil of 333 L.9

Protein binding

Tipiracil does not bind highly to proteins and presents a plasma protein binding below 8%.10

Metabolism

Tipiracil does not undergo much metabolism upon first pass. It is not metabolized by the liver or hepatocytes, nor by the cytochrome P450 enzymes. The only tipiracil-derived metabolite found in very small quantities in human plasma, urine or faeces is 6-hydroxymethyluracil (6-HMU) which is not unique of tipiracil. This metabolite is though to be formed either by enterobacterial metabolism. In plasma, this two metabolites can be found in a proportion of tipiracil 53.1% and 6-HMU 30.9%.8

Route of elimination

The main fraction of tipiracil is excreted unchanged in the mainly in the faeces (49.7%) followed by the urine (27%). From the urine excretion 79.1% is accounted by unchanged tipiracil while 14% is 6-HMU. On the other hand, the faeces elimination analysis was formed by 48.2% unchanged tipiracil and 34.4% 6-HMU.8

Half life

Tipiracil mean elmination half-life is 2.1 hours.6

Clearance

A single 35mg/m2 of TAS-102 in patients with advanced solid tumors produces a clearance rate of tipiracil of 109 L/hr, with a recovery rate of 77% of the total dose.9

Toxicity

TAS-102 is a cytotoxic drug, therefore this combination drug can cause myelosupression, including neutropenia, anemia, thrombocytopenia, and febrile neutropenia. According to pre-clinical studies, TAS-102 presents also embryo-fetal toxicity.1

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbemaciclibThe excretion of Abemaciclib can be decreased when combined with Tipiracil.
AcyclovirThe excretion of Tipiracil can be decreased when combined with Acyclovir.
AmantadineThe excretion of Tipiracil can be decreased when combined with Amantadine.
AmilorideThe excretion of Tipiracil can be decreased when combined with Amiloride.
Aminohippuric acidThe excretion of Tipiracil can be decreased when combined with Aminohippuric acid.
AmiodaroneThe excretion of Tipiracil can be decreased when combined with Amiodarone.
ApalutamideThe excretion of Tipiracil can be decreased when combined with Apalutamide.
BaricitinibThe excretion of Tipiracil can be decreased when combined with Baricitinib.
BictegravirThe excretion of Tipiracil can be decreased when combined with Bictegravir.
BrigatinibThe excretion of Tipiracil can be decreased when combined with Brigatinib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Kish T, Uppal P: Trifluridine/Tipiracil (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. P T. 2016 May;41(5):314-25. [PubMed:27162472]
  2. Lenz HJ, Stintzing S, Loupakis F: TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev. 2015 Nov;41(9):777-83. doi: 10.1016/j.ctrv.2015.06.001. Epub 2015 Jun 6. [PubMed:26428513]
  3. Puthiamadathil JM, Weinberg BA: Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil. Cancer Manag Res. 2017 Oct 3;9:461-469. doi: 10.2147/CMAR.S113320. eCollection 2017. [PubMed:29056855]
  4. Hotchkiss KA, Ashton AW, Schwartz EL: Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. J Biol Chem. 2003 May 23;278(21):19272-9. Epub 2003 Mar 13. [PubMed:12639965]
  5. Peters GJ, Bijnsdorp IV: TAS-102: more than an antimetabolite. Lancet Oncol. 2012 Dec;13(12):e518-9. doi: 10.1016/S1470-2045(12)70426-6. [PubMed:23182191]
  6. Cleary JM, Rosen LS, Yoshida K, Rasco D, Shapiro GI, Sun W: A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Invest New Drugs. 2017 Apr;35(2):189-197. doi: 10.1007/s10637-016-0409-9. Epub 2017 Jan 23. [PubMed:28111727]
  7. Yoshino T, Kojima T, Bando H, Yamazaki T, Naito Y, Mukai H, Fuse N, Goto K, Ito Y, Doi T, Ohtsu A: Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. Cancer Sci. 2016 May;107(5):659-65. doi: 10.1111/cas.12912. Epub 2016 Mar 28. [PubMed:26918279]
  8. Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulkner T, Parise RA, Fawcett P, Pollice L, Mason S, Hague J, Croft M, Nugteren J, Tedder C, Sun W, Chu E, Beumer JH: Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer Chemother Pharmacol. 2016 Mar;77(3):515-26. doi: 10.1007/s00280-016-2965-2. Epub 2016 Jan 19. [PubMed:26787503]
  9. EMA.europa [Link]
  10. EMA.europa [Link]
External Links
PubChem Compound
6323266
PubChem Substance
310265218
ChemSpider
13243748
BindingDB
20079
ChEBI
90879
ChEMBL
CHEMBL235668
Wikipedia
Tipiracil
FDA label
Download (490 KB)
MSDS
Download (30 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
1CompletedTreatmentMetastatic Colorectal Cancers1
1Not Yet RecruitingTreatmentRectal Adenocarcinoma / Stage IIA Rectal Cancer AJCC v8 / Stage IIB Rectal Cancer AJCC v8 / Stage III Rectal Cancer AJCC v8 / Stage IIIA Rectal Cancer AJCC v8 / Stage IIIB Rectal Cancer AJCC v8 / Stage IIIC Rectal Cancer AJCC v81
1RecruitingTreatmentAdvanced or Metastatic Colorectal Cancer (mCRC) / Advanced or Metastatic Solid Tumors1
1RecruitingTreatmentColorectal Cancers1
1RecruitingTreatmentGastric Adenocarcinoma / Gastrooesophageal Cancer1
1RecruitingTreatmentHepatic Metastases / Malignant Neoplasm of Colon / Rectal Carcinoma1
1RecruitingTreatmentMetastatic Colon Carcinoma / Metastatic Colorectal Carcinoma / Metastatic Rectal Carcinoma / RAS Family Gene Mutation / Stage III Colon Cancer AJCC v7 / Stage III Colorectal Cancer AJCC v7 / Stage III Rectal Cancer AJCC v7 / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIA Rectal Cancer AJCC v7 / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIB Rectal Cancer AJCC v7 / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Colorectal Cancer AJCC v7 / Stage IIIC Rectal Cancer AJCC v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Colorectal Cancer AJCC v7 / Stage IV Rectal Cancer AJCC v7 / Stage IVA Colon Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
1RecruitingTreatmentPretreated Metastatic Colorectal Cancer1
1RecruitingTreatmentRectal Adenocarcinoma / Recurrent Rectal Carcinoma / Stage IV Rectal Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
1, 2CompletedTreatmentColorectal Cancers1
1, 2Not Yet RecruitingTreatmentCRC1
1, 2RecruitingTreatmentAdvanced Gastric Cancer / Colorectal Adenocarcinoma / Gastric Adenocarcinoma / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Stage IV Colorectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer / Unresectable Pancreatic Carcinoma1
1, 2RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentCholangiocarcinomas / Stage III Gallbladder Cancer AJCC V7 / Stage IIIA Gallbladder Cancer AJCC v7 / Stage IIIB Gallbladder Cancer AJCC v7 / Stage IV Gallbladder Cancer AJCC v7 / Stage IVA Gallbladder Cancer AJCC v7 / Stage IVB Gallbladder Cancer AJCC v71
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentPreviously Treated Metastatic Colorectal Cancer1
2Active Not RecruitingTreatmentSquamous Cell Lung Carcinoma1
2CompletedTreatmentRefractory, metastatic Colorectal cancer1
2Not Yet RecruitingTreatmentAdvanced Bile Duct Carcinoma / Advanced Gallbladder Carcinoma / Refractory Bile Duct Carcinoma / Refractory Gallbladder Carcinoma / Stage III Distal Bile Duct Cancer AJCC v8 / Stage III Gallbladder Cancer AJCC v8 / Stage III Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIA Distal Bile Duct Cancer AJCC v8 / Stage IIIA Gallbladder Cancer AJCC v8 / Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIB Distal Bile Duct Cancer AJCC v8 / Stage IIIB Gallbladder Cancer AJCC v8 / Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8 / Stage IV Distal Bile Duct Cancer AJCC v8 / Stage IV Gallbladder Cancer AJCC v8 / Stage IV Intrahepatic Bile Duct Cancer AJCC v8 / Stage IVA Gallbladder Cancer AJCC v8 / Stage IVB Gallbladder Cancer AJCC v81
2Not Yet RecruitingTreatmentBRAF V600 Wild Type / KRAS Gene Mutation Negative / Metastatic Colon Adenocarcinoma / Metastatic Colorectal Carcinoma / Metastatic Rectal Adenocarcinoma / NRAS Gene Mutation Negative / Progressive Disease / RAS Wild Type / Stage IV Colon Cancer AJCC v8 / Stage IV Colorectal Cancer AJCC v8 / Stage IV Rectal Cancer AJCC v8 / Stage IVA Colon Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVA Rectal Cancer AJCC v8 / Stage IVB Colon Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVB Rectal Cancer AJCC v8 / Stage IVC Colon Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 / Stage IVC Rectal Cancer AJCC v81
2Not Yet RecruitingTreatmentCholangiocarcinomas1
2Not Yet RecruitingTreatmentClinical Stage IIA Esophageal Adenocarcinoma AJCC v8 / Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage III Esophageal Adenocarcinoma AJCC v8 / Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 / Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v81
2Not Yet RecruitingTreatmentHigh-grade Extra Pulmonary Neuroendocrine Cancer1
2Not Yet RecruitingTreatmentKRAS Gene Mutation / Metastatic Colorectal Carcinoma / NRAS Gene Mutation / Stage III Colorectal Cancer AJCC v8 / Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 / Unresectable Carcinoma1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Malignant Neoplasm of Stomach1
2RecruitingTreatmentBile Duct Carcinoma / Cholangiocarcinomas1
2RecruitingTreatmentRefractory Colorectal Carcinoma / Stage III Colorectal Cancer AJCC v8 / Stage IIIA Colorectal Cancer AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81
2SuspendedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2, 3RecruitingTreatmentColorectal Cancers / Metastasis1
3RecruitingTreatmentMetastatic Colorectal Cancers2
3WithdrawnTreatmentCarcinoma NOS / Metastatic Colorectal Cancers1
Not AvailableRecruitingNot AvailableMetastatic Colorectal Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7799783No2010-09-212026-12-16Us
US5744475No1998-04-282016-03-28Us
US6479500No2002-11-122020-03-16Us
US9527833No2016-12-272034-06-17Us
USRE46284No2017-01-242026-12-16Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)245ºC (decomposition)Not Available
water solubility5 mg/ml (warmed)Sigma-aldrich MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.731 mg/mLALOGPS
logP-0.21ALOGPS
logP-2ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)7.28ChemAxon
pKa (Strongest Basic)11.55ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area85.29 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity69.89 m3·mol-1ChemAxon
Polarizability22.48 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Halopyrimidines
Alternative Parents
Pyrimidones / Aryl chlorides / Hydropyrimidines / Imidolactams / N-alkylpyrrolidines / Vinylogous amides / Heteroaromatic compounds / Ureas / Lactams / Carboximidamides
show 7 more
Substituents
Halopyrimidine / Pyrimidone / Aryl chloride / Aryl halide / Hydropyrimidine / N-alkylpyrrolidine / Imidolactam / Pyrrolidine / Heteroaromatic compound / Vinylogous amide
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring pentosyl groups
Specific Function
May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in v...
Gene Name
TYMP
Uniprot ID
P19971
Uniprot Name
Thymidine phosphorylase
Molecular Weight
49954.965 Da

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Carrier
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ: Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017 Oct 6;86:197-206. doi: 10.1016/j.ejca.2017.08.033. [PubMed:28992563]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Carrier
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
References
  1. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ: Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017 Oct 6;86:197-206. doi: 10.1016/j.ejca.2017.08.033. [PubMed:28992563]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Martinez-Perez J, Riesco-Martinez MC, Garcia-Carbonero R: The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Expert Opin Drug Saf. 2018 Jun;17(6):643-650. doi: 10.1080/14740338.2018.1475557. Epub 2018 May 23. [PubMed:29745737]
  2. Tipiracil EMA [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
References
  1. Martinez-Perez J, Riesco-Martinez MC, Garcia-Carbonero R: The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Expert Opin Drug Saf. 2018 Jun;17(6):643-650. doi: 10.1080/14740338.2018.1475557. Epub 2018 May 23. [PubMed:29745737]
  2. Tipiracil EMA [File]

Drug created on November 27, 2015 13:26 / Updated on September 02, 2019 21:47